Replies to post #77051 on Biotech Values

[rkrw]

For example, it it costs $7500 to produce per patient, $30,000 gives them a 75% gross margin, $50,000, 85%. Big difference. Rumored pricing is all over the place. I'd like to know how much it costs per patient not speculation on margins with no idea what dndn is planning to charge. Realistically we're not going to know dndn's pricing model for certain until approval.

[AlpineBV_Miller]

Miller’s main point is that Provenge will have a lower gross margin than a typical biopharmaceutical. We won’t know how much lower until we know the price, but I think it’s clear that Provenge’s gross margin will be on the low side at any conceivable pricing level.

Dew's right, but I bet we'll be in the right range around 70%. I think we've got better than an average guess at what the company plans to charge after umpteen years of covering the story.